Latest News about Novo Nordisk A/S
Recent news which mentions Novo Nordisk A/S
   Cramer's Lightning Round: 'I'd be careful' with Novo Nordisk
   
  
  January 07, 2025
  From CNBC.com News
 
   Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
   
  
  December 24, 2024
  From CNBC.com News
 
   FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
   
  
  December 24, 2024
  From CNBC.com News
 
   CNBC Daily Open: With cooler-than-expected PCE, would the Fed’s dot plot have looked different?
   
  
  December 22, 2024
  From CNBC.com News
 
   FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
   
  
  December 20, 2024
  From CNBC.com News
 From CNBC.com News
 
   Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
   
  
  December 18, 2024
  From CNBC.com News
 
   Europe's economy faces a bumpy ride in 2025. Here are 5 things to watch
   
  
  December 18, 2024
  From CNBC.com News
 
   Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
   
  
  December 17, 2024
  From CNBC.com News
 
   Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
   
  
  December 11, 2024
  From CNBC.com News
 
   Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
   
  
  December 11, 2024
  From CNBC.com News
 
   The weight-loss drug boom has become one of the internet's biggest scams
   
  
  December 08, 2024
  From CNBC.com News
 
   Healthy Returns: Wall Street mulls over Amgen’s weight loss drug data
   
  
  December 05, 2024
  From CNBC.com News
 
   Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
   
  
  December 05, 2024
  From CNBC.com News
 
   Hiccups in ETFs tracking MicroStrategy occurring as bull market fuels trading boom in single-stock funds
   
  
  December 04, 2024
  From CNBC.com News
 
   Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
   
  
  December 04, 2024
  From CNBC.com News
 
   5 things to know before the stock market opens Tuesday
   
  
  November 26, 2024
  From CNBC.com News
 
   Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
   
  
  November 26, 2024
  From CNBC.com News
 From CNBC.com News
 
   Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
   
  
  November 08, 2024
  From CNBC.com News
 
   Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity
   
  
  October 31, 2024
  From CNBC.com News
 
   Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
   
  
  October 30, 2024
  From CNBC.com News
 
   Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
   
  
  October 24, 2024
  From CNBC.com News
 
   Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
   
  
  
  October 23, 2024
  From Benzinga
 From CNBC.com News
 
   Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
   
  
  October 23, 2024
  From CNBC.com News
 
   Healthy Returns: Covering weight loss drugs could cost Medicare $35 billion through 2034
   
  
  October 15, 2024
  From CNBC.com News
 
   Cramer's Lightning Round: Uranium Energy is 'the real deal'
   
  
  October 14, 2024
  From CNBC.com News
 
   Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
   
  
  October 11, 2024
  From CNBC.com News
 
   Ozempic underworld: Inside the black market of obesity drugs
   
  
  October 09, 2024
  From CNBC.com News
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
